The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
The MoU lays the groundwork for deep academic and research collaboration in pharmaceutical technologies
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
This partnership represents a systemic shift from awareness to large-scale action for 57 lakh children
Under the deal, Quiver will receive an undisclosed advance payment and research support
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
The funding comes under the AHG Catalysing Innovation Awards, part of the Addiction Healthcare Goals programme led by the Office for Life Sciences
Subscribe To Our Newsletter & Stay Updated
